Inspections, Compliance, Enforcement, and Criminal Investigations
Memorial Hermann-Texas Medical Center 19-Oct-06
Department of Health and Human Services
Public Health Service
Southwest Regional Office
October 19, 2006
Via Federal Express - Next Day
Re: MQSA Inspection ID # 116368
Chief Executive Officer
Memorial Hermann-Texas Medical Center
6411 Fannin Street
Houston, TX 77030
RE: Memorial Hermann Imaging and Breast Center
Dear Ms . Romans,
On September 21, 2006, a representative of the Food and Drug Administration (FDA) conducted an investigation at your facility which revealed a serious problem involving the conduct of mammography . Under the Mammography Quality Standards Act of 1992 ("MQSA") which is codified in Section 263b of Title 42 of the United States Code (USC), you must meet specific requirements to practice mammography. These requirements serve to protect the health of women by assuring that a facility can perform quality mammography.
The problem identified during this investigation constitutes a violation of the MQSA as identified below.
The system to communicate results for some patient examinations performed during the month of October 2005 was not adequate for your site because:
-There was no system in place to provide timely medical reports
-There was no system in place to provide timely lay summaries [See 21 CFR 900.12(c)].
Because this violation may be indicative of serious underlying problems that could compromise the quality of mammography at your facility, FDA may take additional actions including, but not limited to, the following:
requiring your facility to undergo an Additional Mammography Review
placing your facility under a Directed Plan of Correction
charging your facility for the cost of on-site monitoring
requiring your facility to notify patients who received mammograms at your facility, and their referring physicians, of the deficiencies, the
potential harm resulting from such deficiencies, appropriate remedial measures, and other relevant information
seeking civil money penalties up to $11,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA standards
seeking to suspend or revoke your facility's FDA certificate
seeking a court injunction against your facility
See 42 USC 263b(h)-(j) and 21 CFR 900.12(j).
You should respond in writing to FDA within fifteen (15) working days from the date you receive this letter. Your response should address the findings listed above and include:
1. the specific steps you have taken, or will take to correct all of the violations noted in this letter, including projected timeframes for implementing those steps;
2. The specific steps you have taken, or will take, to prevent the recurrence of similar violations, including projected timeframes for implementing those steps.
Please submit your response to this letter to:
Deborah M . McGee
Food and Drug Administration
4040 N. Central Expressway, Suite 900
Dallas, TX 75204
Finally, you should understand that there are many requirements pertaining to mammography. This letter pertains only to violations related to the recent investigation of your facility and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda.gov/cdrh/mammography/index.html.
If you have additional or more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Deborah M. McGee, M.S., Southwest Regional Compliance Officer, by telephoning (214) 253-4935.
Dennis E . Baker
Regional Food and Drug Director
Southwest Regional Office